CELC stock forecast, quote, news & analysis
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors... Show more
Why Celcuity (CELC) Stock Is Down -32.6% in the Last 30 Days
Key Takeaways
- Celcuity shares have fallen roughly 33% over the last 30 days, from a close of $82.58 on September 16 to about $55.63 as of mid-October, even as its first drug, REVTORPYK, reached the U.S. market on September 30.
- The decline reflects a broader pullback from a 52-week high near $151, as investors reset expectations following the July 14 FDA approval of REVTORPYK (gedatolisib).
- The company reported a widened Q2 2026 net loss of $78.9 million as it scaled up commercial infrastructure ahead of launch.
- Heavy insider selling, including a $317.75 million share sale by Baker Bros. Advisors, and elevated short interest have weighed on sentiment.
- Despite the sell-off, Wall Street consensus remains a Strong Buy, with an average price target around $157.
Celcuity (CELC) Company Overview and Market Position
Celcuity Inc. is a Minneapolis-based biotechnology company developing targeted therapies for solid tumors. Its lead asset, gedatolisib—marketed as REVTORPYK—is the first and only approved drug designed to inhibit all four class I PI3K isoforms plus both mTOR complexes, enabling comprehensive inhibition of the PI3K/AKT/mTOR (PAM) pathway that drives cancer cell growth.
In July 2026, the FDA approved REVTORPYK in combination with fulvestrant, with or without Pfizer's (PFE) palbociclib, for adults with HR-positive, HER2-negative, PIK3CA wild-type advanced or metastatic breast cancer. This approval moved Celcuity from a clinical-stage developer into a commercial-stage company, and management estimates a U.S. addressable market of roughly $5 billion to $6 billion in the second-line setting. The company is also advancing label-expansion, first-line, and prostate cancer programs.
Celcuity (CELC) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CELC has declined about 32.6%, sliding from a closing price of $82.58 on September 16 to roughly $55.63 in mid-October. The stock has traded in a clear downtrend during this stretch, with a brief rally around the late-September launch giving way to renewed selling into October.
The quarterly picture is similar in direction but broader in scope. Following the mid-July FDA approval, shares closed at $91.51 on July 15 and have since declined roughly 39%, while remaining far below the 52-week high near $151. The multi-month trend shows fading momentum from a steep multi-year run, with the near-term sell-off contrasting against a still-positive one-year return.
What Drove CELC Stock Price in the Last 30 Days
Several verified factors have pressured the stock recently. The commercial launch of REVTORPYK on September 30, 2026, was a long-awaited milestone, but the market had largely priced in the approval and initial launch, and the event did not provide a fresh catalyst. A delayed launch timeline—first disclosed in July when management guided to a late-third-quarter rollout—continued to temper near-term revenue expectations.
Sentiment has also been weighed down by corporate insider activity. Baker Bros. Advisors sold 3.1 million shares for roughly $317.75 million in July, and broader insider selling has been reported with limited insider buying. Elevated short interest, reported above 25% of the float, has added to selling pressure. Meanwhile, the company's widening net loss—$78.9 million in Q2 2026 versus $45.3 million a year earlier—reflects rising launch-related operating expenses, and several law firms announced shareholder investigations following the approval-related disclosure.
What Drove CELC Stock Performance Over the Last Quarter
The quarterly decline traces back to the reaction to the July 14 FDA approval. Although REVTORPYK became Celcuity's first marketed product, the stock fell 17.6% on July 15 after management guided to a late-Q3 launch and disclosed tolerability warnings and higher-than-expected discontinuation rates in the label. Analysts, including those at Leerink Partners and Stifel, noted the extended launch timeline relative to expectations.
This reset followed an earlier pullback in June, when ASCO data on the PIK3CA-mutant cohort of the Phase 3 VIKTORIA-1 trial—despite halving the risk of disease progression or death versus alpelisib—came in below "lofty" investor expectations built on earlier testing. The stock's rapid prior appreciation, combined with a $500 million convertible notes offering, dilution concerns, and insider selling, has kept the shares under pressure even as the underlying clinical and regulatory story has advanced.
Trending AI Robots
For traders looking to complement their own analysis with automated strategies, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading bots. Tickeron provides hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary by strategy, timeframe, and performance metrics, giving investors a way to explore systematic approaches across different market conditions. Exploring the page can help you see which automated strategies are currently gaining traction.
CELC Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on early prescription and revenue uptake from the REVTORPYK launch, which will be the first real test of the commercial thesis. Management has indicated plans to submit a regulatory filing for label expansion into PIK3CA-mutant patients, supported by the VIKTORIA-1 mutant cohort, which could meaningfully expand the addressable market. Progress on the first-line Phase 3 VIKTORIA-2 program and the metastatic castration-resistant prostate cancer study represent additional longer-term catalysts.
Key risks include execution on the commercial ramp, ongoing operating losses and cash burn, potential dilution from the convertible notes, insider selling, and elevated short interest. Investors should also monitor broader biotech sentiment and any updates to analyst price targets as launch data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for CELC turns positive, indicating new upward trend
CELC saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned positive. In 86 of the 98 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CELC's RSI Indicator exited the oversold zone, 20 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for CELC just turned positive on October 22, 2026. Looking at past instances where CELC's MACD turned positive, the stock continued to rise in 43 of 50 cases over the following month. The odds of a continued upward trend are 86%.
Following a +5.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELC advanced for three days, in 249 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CELC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CELC entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CELC's P/B Ratio (-266.922) is very low in comparison to the industry average of (3.051). P/E Ratio (-16.214) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 62 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. CELC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company develops novel diagnostic tests
Industry Biotechnology